Safety and Efficacy of Fenofibrate as a Treatment for Huntington's Disease

• Status: Active, not recruiting
• Trial end date: 2021-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this research study is to study the safety and efficacy of fenofibrate, an FDA-approved drug for high cholesterol and/or elevated triglyerides (fats), as a treatment for Huntington's disease (HD). Subjects who meet the entry criteria will be randomized (3:1) to either 145mg of fenofibrate or placebo.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, Irvine
• Treatments: Fenofibrate

Criteria

Inclusion Criteria:

• An adult of either sex, ages 25-85 inclusive,

• Have proficiency with written and spoken English and corrected vision or hearing to complete the cognitive testing,

• Are able to give informed consent,

• Have good overall health status with no known problems anticipated over the course of the trial,

• Have a diagnosis of HD supported by positive gene test within the past 6 months.

Exclusion Criteria:

• Other major neurological disease [e.g., multiple sclerosis, parkinson's disease, cortical stroke, etc]

• Clinically significant hepatic or renal disease,

• Current or recent (< 1 month) use of dopamine blocking agents such as tetrabenazine, anticonvulsants, neuroleptics, HAART, antiemetics, and antipsychotics for any reason,

• Current use of Warfarin (Coumadin). Enrollment in another investigational drug study within the prior three months.